Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONGeneric

HEXABRIX

IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM

Standard Dose
39.3%;19.6%
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview HEXABRIX is listed in Drugs@FDA under application 018905 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM Form and strength INJECTABLE;INJECTION - 39.3%;19.6% Sponsor GUERBET Submission history Latest submission status date: 2017-04-05 00:00:00.

Structured Monograph

Clinical summary

Approval overview HEXABRIX is listed in Drugs@FDA under application 018905 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM Form and strength INJECTABLE;INJECTION - 39.3%;19.6% Sponsor GUERBET Submission history Latest submission status date: 2017-04-05 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.